EA032602B1 - Положительные аллостерические модуляторы мускаринового рецептора м1 - Google Patents
Положительные аллостерические модуляторы мускаринового рецептора м1 Download PDFInfo
- Publication number
- EA032602B1 EA032602B1 EA201792594A EA201792594A EA032602B1 EA 032602 B1 EA032602 B1 EA 032602B1 EA 201792594 A EA201792594 A EA 201792594A EA 201792594 A EA201792594 A EA 201792594A EA 032602 B1 EA032602 B1 EA 032602B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- carboxamide
- benzo
- oxazine
- cis
- hydroxycyclohexyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrophonic Musical Instruments (AREA)
- Liquid Crystal Display Device Control (AREA)
- Arrangement And Driving Of Transmission Devices (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2851CH2015 | 2015-06-08 | ||
| PCT/IB2016/000771 WO2016198937A1 (en) | 2015-06-08 | 2016-06-08 | Muscarinic m1 receptor positive allosteric modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201792594A1 EA201792594A1 (ru) | 2018-06-29 |
| EA032602B1 true EA032602B1 (ru) | 2019-06-28 |
Family
ID=56411822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201792594A EA032602B1 (ru) | 2015-06-08 | 2016-06-08 | Положительные аллостерические модуляторы мускаринового рецептора м1 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10308620B2 (ko) |
| EP (1) | EP3303331B1 (ko) |
| JP (1) | JP6466602B2 (ko) |
| KR (1) | KR102052058B1 (ko) |
| CN (1) | CN107922400B (ko) |
| AU (1) | AU2016276139B2 (ko) |
| BR (1) | BR112017026272B1 (ko) |
| CA (1) | CA2987843C (ko) |
| CY (1) | CY1121693T1 (ko) |
| DK (1) | DK3303331T3 (ko) |
| EA (1) | EA032602B1 (ko) |
| ES (1) | ES2719626T3 (ko) |
| HK (1) | HK1247919A1 (ko) |
| HR (1) | HRP20190624T1 (ko) |
| HU (1) | HUE044902T2 (ko) |
| IL (1) | IL255994B (ko) |
| LT (1) | LT3303331T (ko) |
| MA (1) | MA43913B1 (ko) |
| MD (1) | MD3303331T2 (ko) |
| ME (1) | ME03379B (ko) |
| MX (1) | MX2017015961A (ko) |
| NZ (1) | NZ737892A (ko) |
| PL (1) | PL3303331T3 (ko) |
| PT (1) | PT3303331T (ko) |
| RS (1) | RS58665B1 (ko) |
| SI (1) | SI3303331T1 (ko) |
| TR (1) | TR201904639T4 (ko) |
| WO (1) | WO2016198937A1 (ko) |
| ZA (1) | ZA201708108B (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50402A (fr) | 2017-10-18 | 2021-05-19 | Suven Life Sciences Ltd | Composés hétéroaryle utilisés en tant que modulateurs allostériques positifs du récepteur muscarinique m1 |
| JP7110338B2 (ja) | 2017-10-27 | 2022-08-01 | スヴェン・ライフ・サイエンシーズ・リミテッド | ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類 |
| US20220152005A1 (en) * | 2019-04-04 | 2022-05-19 | Andrew Coop | Methods of using muscarinic antagonists in the treatment of depression |
| KR102285472B1 (ko) | 2019-06-14 | 2021-08-03 | 엘지전자 주식회사 | 음향의 이퀄라이징 방법과, 이를 구현하는 로봇 및 ai 서버 |
| CN110606827B (zh) * | 2019-09-26 | 2023-03-14 | 西安凯立新材料股份有限公司 | 一步法合成甲氨基吡啶类化合物的方法 |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015028483A1 (en) * | 2013-08-30 | 2015-03-05 | F. Hoffmann-La Roche Ag | Pyrrolopyridine or pyrazolopyridine derivatives |
| WO2015049574A1 (en) * | 2013-10-01 | 2015-04-09 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
| WO2015080904A1 (en) * | 2013-11-27 | 2015-06-04 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1183847A (en) | 1981-10-01 | 1985-03-12 | Georges Van Daele | N-(3-hydroxy-4-piperidinyl)benzamide derivatives |
| WO2007100366A2 (en) | 2005-12-05 | 2007-09-07 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
| WO2011149801A1 (en) | 2010-05-28 | 2011-12-01 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide m1 receptor positive allosteric modulators |
| JP2014076948A (ja) | 2011-02-09 | 2014-05-01 | Astellas Pharma Inc | イソキノリンアミド誘導体 |
| WO2013129622A1 (ja) * | 2012-03-02 | 2013-09-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| GB201409044D0 (en) * | 2014-05-21 | 2014-07-02 | Ucl Business Plc | New compounds |
-
2016
- 2016-06-08 ME MEP-2019-99A patent/ME03379B/me unknown
- 2016-06-08 JP JP2017563539A patent/JP6466602B2/ja active Active
- 2016-06-08 AU AU2016276139A patent/AU2016276139B2/en active Active
- 2016-06-08 TR TR2019/04639T patent/TR201904639T4/tr unknown
- 2016-06-08 MD MDE20180352T patent/MD3303331T2/ro unknown
- 2016-06-08 ES ES16738860T patent/ES2719626T3/es active Active
- 2016-06-08 NZ NZ737892A patent/NZ737892A/en unknown
- 2016-06-08 HU HUE16738860 patent/HUE044902T2/hu unknown
- 2016-06-08 EA EA201792594A patent/EA032602B1/ru unknown
- 2016-06-08 BR BR112017026272-0A patent/BR112017026272B1/pt active IP Right Grant
- 2016-06-08 CN CN201680040849.9A patent/CN107922400B/zh active Active
- 2016-06-08 US US15/580,632 patent/US10308620B2/en active Active
- 2016-06-08 PT PT16738860T patent/PT3303331T/pt unknown
- 2016-06-08 MA MA43913A patent/MA43913B1/fr unknown
- 2016-06-08 EP EP16738860.2A patent/EP3303331B1/en active Active
- 2016-06-08 KR KR1020187000574A patent/KR102052058B1/ko active IP Right Grant
- 2016-06-08 MX MX2017015961A patent/MX2017015961A/es active IP Right Grant
- 2016-06-08 PL PL16738860T patent/PL3303331T3/pl unknown
- 2016-06-08 CA CA2987843A patent/CA2987843C/en active Active
- 2016-06-08 SI SI201630220T patent/SI3303331T1/sl unknown
- 2016-06-08 WO PCT/IB2016/000771 patent/WO2016198937A1/en active Application Filing
- 2016-06-08 RS RS20190440A patent/RS58665B1/sr unknown
- 2016-06-08 DK DK16738860.2T patent/DK3303331T3/en active
- 2016-06-08 LT LTEP16738860.2T patent/LT3303331T/lt unknown
-
2017
- 2017-11-29 ZA ZA2017/08108A patent/ZA201708108B/en unknown
- 2017-11-29 IL IL255994A patent/IL255994B/en active IP Right Grant
-
2018
- 2018-06-05 HK HK18107344.8A patent/HK1247919A1/zh unknown
-
2019
- 2019-04-01 HR HRP20190624TT patent/HRP20190624T1/hr unknown
- 2019-04-05 CY CY20191100379T patent/CY1121693T1/el unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015028483A1 (en) * | 2013-08-30 | 2015-03-05 | F. Hoffmann-La Roche Ag | Pyrrolopyridine or pyrazolopyridine derivatives |
| WO2015049574A1 (en) * | 2013-10-01 | 2015-04-09 | Eisai R&D Management Co., Ltd. | 4-azaindole derivatives |
| WO2015080904A1 (en) * | 2013-11-27 | 2015-06-04 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA032602B1 (ru) | Положительные аллостерические модуляторы мускаринового рецептора м1 | |
| JP4649413B2 (ja) | アルツハイマー病の治療用のベンジルエーテル及びベンジルアミノβ−セクレターゼ阻害薬 | |
| IL279428B1 (en) | Pyridinyl and pyrazinyl -(aza)indolesulfonamides | |
| EP2349256B1 (en) | Heterocyclic benzimidazoles as trpm8 modulators | |
| EA018521B1 (ru) | Гетероциклические производные | |
| CA3137091A1 (en) | N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis | |
| EA024248B1 (ru) | Соединения (тиено[2,3-b][1,5]бензоксазепин-4-ил)пиперазин-1-ила, обладающие двойной активностью обратных агонистов рецепторов h1/антагонистов рецепторов 5-ht | |
| EA030034B1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| JP2024501641A (ja) | 置換大環状化合物及び関連する治療方法 | |
| JP2023554282A (ja) | 置換ピペリジノ化合物及び関連する治療方法 | |
| EP1943226A2 (en) | Phenol ethers as modulators of the opioid receptors | |
| JP7104783B2 (ja) | ムスカリンｍ１受容体陽性アロステリックモジュレーターであるヘテロアリール化合物 | |
| JP3280040B2 (ja) | アミノベンゼン化合物 | |
| JP6298172B2 (ja) | Ｇｐｒ１４２アゴニスト化合物 | |
| AU2022267220A1 (en) | Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity | |
| TWI564300B (zh) | 經取代之［（５Ｈ－吡咯［２，１－ｃ］［１，４］苯二氮呯－１１－基）哌嗪－１－基］－２，２－二甲基丙酸化合物作為雙重活性Ｈ１反向促進劑／５－ＨＴ2Ａ拮抗劑 | |
| CA3219506A1 (en) | Substituted fused bicyclic macrocyclic compounds and related methods of treatment | |
| EP4347604A1 (en) | Substituted carbamate macrocyclic compounds and related methods of treatment | |
| KR20160101199A (ko) | Gpr142 효능제 화합물 |